Page last updated: 2024-11-13
doxoform
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
doxoform: a doxorubicin-formaldehyde conjugate; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 24202589 |
| CHEMBL ID | 406294 |
| MeSH ID | M0332016 |
Synonyms (5)
| Synonym |
|---|
| CHEMBL406294 |
| doxoform |
| nsc-699490 |
| nsc699490 |
| (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7-[[4-methyl-1-[[4-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]-2,3a,4,6,7,7a-hexahydropyrano[4,3-d][1,3]oxazol-1-yl]methyl]-2,3a,4 |
Research Excerpts
Overview
Doxoform is a prodrug of doxazolidine. It is a monomeric doxorubicin formaldehyde-oxazolidines.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Doxoform is a prodrug of doxazolidine, a monomeric doxorubicin formaldehyde-oxazolidine." | ( Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA. Barthel, BL; Burkhart, DJ; Hagadorn, JR; Koch, TH; Post, GC, 2005) | 1.05 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID101613 | compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells. | 1997 | Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16 | Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. |
| AID103085 | Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR). | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells. |
| AID103913 | Compound was tested for its toxicity against human breast cancer cells(MCF-7) | 1998 | Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8 | Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells. |
| AID103093 | compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells. | 1997 | Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16 | Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||